Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03933631 · ClinicalTrials.gov registry record · Phase 3
Pilocarpine Use After Kahook Goniotomy
A Phase 3 study of Glaucoma, sponsored by Montefiore Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 142
- Enrollment target
- 2
- Study locations
NCT03933631 is a Phase 3 study of Glaucoma that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 142 participants, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03933631, a Phase 3 study of Glaucoma, is actively recruiting participants, sponsored by Montefiore Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 142 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to determine whether using pilocarpine provides added benefit to the success of combined cataract + Kahook Dual Blade (KDB) surgery.
Conditions Studied
Interventions
- DRUG Prednisolone
- DRUG Pilocarpine
- DRUG Ofloxacin
Study Locations (2)
New York
- Montefiore Wakefield Campus - The Bronx
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03933631
The ClinicalTrials.gov registry entry for NCT03933631 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (84% lower). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which Prednisolone is the first listed.
NCT03933631 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03933631 about?
NCT03933631 is a clinical study titled "Pilocarpine Use After Kahook Goniotomy". The goal of this study is to determine whether using pilocarpine provides added benefit to the success of combined cataract + Kahook Dual Blade (KDB) surgery.
What is the current status of trial NCT03933631?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2019-05-01. Estimated completion is 2028-12.
What conditions does trial NCT03933631 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT03933631?
The interventions under investigation include: Prednisolone (DRUG), Pilocarpine (DRUG), Ofloxacin (DRUG).
Who is sponsoring clinical trial NCT03933631?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03933631 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
COMPLETED · Phase 3
-
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
-
Functional and Structural Imaging for Glaucoma
RECRUITING
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.